Novartis Pharmaceuticals Corporation
- All
- News
-
GSK Buys Novartis Stake In Consumer Healthcare Venture For $13 billion
The deal is set to complete in the second quarter subject to the necessary approvals.
-
In Fight For GSK's Advair, Generic Firms Step Carefully On Price
Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business without a race to the bottom on price.
-
Asset Sales Pump Up Novartis Profits
Net profits jumped 73 per cent at Novartis last year to $17.7 billion thanks to asset sales, the Swiss pharmaceutical giant said Wednesday, but without the disposals its performance flagged.
-
Alembic Pharma Arm Ties Up With Novartis for Drug Development
As per the agreement, Switzerland-based Rhizen will receive an upfront payment and is eligible to receive development, regulatory and sale milestones payments, it added.
-
Sun Pharma Gets US Regulator's Nod for Cancer Treatment Drug
Drug major Sun Pharmaceutical Industries on Friday said one of its subsidiaries has received approval of the US Food and Drug Administration (FDA) to manufacture and market generic version of Novartis' Gleevec, used in treatment of cancer, in America.
-
Drug Pricing: Don't Take Coercive Steps Against Cipla, Others, Says Court
The Delhi High Court on Tuesday told the government not to take any coercive action against pharmaceutical companies including Novartis India Limited and Cipla Ltd in connection with the notices issued to them for allegedly not ensuring implementation of the revised drug pricing of 2013.
-
Novartis Gets US Regulator Warning Letter for 2 Plants in India
The warning letter observations follow USFDA inspection at both sites in August 2014 and are related to deficiencies in current good manufacturing practice (cGMP) for finished pharmaceuticals, it added.
-
Novartis India Posts Two-Fold Jump in Q4 Profit
Pharmaceuticals firm Novartis India on Wednesday reported a jump of over two-fold in standalone net at Rs 51.94 crore for the quarter ended March, 2015.
-
Complaint Against Sun Pharma for Anti-Trust Violations in US
Drug major Sun Pharmaceutical Industries on Friday said it is reviewing a complaint filed against it and its subsidiaries by Meijer Inc alleging anti-trust and other violations in connection with Ranbaxy securing market exclusivity for certain products.
-
Lupin Launches Generic Diovan Tablets in US
Lupin Pharmaceuticals Inc, the US-based subsidiary of the company, has launched its Valsartan tablets in strengths of 40 mg, 80 mg, 160 mg and 320 mg in the US market after getting nod from the US Food and Drug Administration (USFDA), Lupin Ltd said in a statement.
-
Drug Pricing Regulator Slaps Rs 300 Crore Penalty on Novartis: Report
Drug major Novartis has been slapped with a Rs 300 crore penalty by the National Pharmaceutical Pricing Authority (NPPA) for overcharging consumers on sale of Voveran, its best-selling painkiller.
-
Novartis reshapes business via deals with GSK and Lilly
The overhaul is part of a major realignment in the global pharmaceuticals industry as it strives to cope with a clampdown in health spending by cash-strapped governments.
-
Big Pharma pushes for US action against India over patent worries: report
Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.
-
Ranbaxy faces more regulatory scrutiny after US ban
Ranbaxy Laboratories Ltd has been hit by more regulatory scrutiny sparked by a US ban on the bulk of its drugs, in a backlash that could bump up compliance costs and erode profitability among some Indian makers of generic drugs.
-
Novartis to cut or transfer up to 4,000 pharma jobs: report
Swiss drugs group Novartis is planning to cut or transfer up to 4,000 jobs, newspaper NZZ am Sonntag reported on Sunday, citing an internal email.
-
GSK Buys Novartis Stake In Consumer Healthcare Venture For $13 billion
The deal is set to complete in the second quarter subject to the necessary approvals.
-
In Fight For GSK's Advair, Generic Firms Step Carefully On Price
Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business without a race to the bottom on price.
-
Asset Sales Pump Up Novartis Profits
Net profits jumped 73 per cent at Novartis last year to $17.7 billion thanks to asset sales, the Swiss pharmaceutical giant said Wednesday, but without the disposals its performance flagged.
-
Alembic Pharma Arm Ties Up With Novartis for Drug Development
As per the agreement, Switzerland-based Rhizen will receive an upfront payment and is eligible to receive development, regulatory and sale milestones payments, it added.
-
Sun Pharma Gets US Regulator's Nod for Cancer Treatment Drug
Drug major Sun Pharmaceutical Industries on Friday said one of its subsidiaries has received approval of the US Food and Drug Administration (FDA) to manufacture and market generic version of Novartis' Gleevec, used in treatment of cancer, in America.
-
Drug Pricing: Don't Take Coercive Steps Against Cipla, Others, Says Court
The Delhi High Court on Tuesday told the government not to take any coercive action against pharmaceutical companies including Novartis India Limited and Cipla Ltd in connection with the notices issued to them for allegedly not ensuring implementation of the revised drug pricing of 2013.
-
Novartis Gets US Regulator Warning Letter for 2 Plants in India
The warning letter observations follow USFDA inspection at both sites in August 2014 and are related to deficiencies in current good manufacturing practice (cGMP) for finished pharmaceuticals, it added.
-
Novartis India Posts Two-Fold Jump in Q4 Profit
Pharmaceuticals firm Novartis India on Wednesday reported a jump of over two-fold in standalone net at Rs 51.94 crore for the quarter ended March, 2015.
-
Complaint Against Sun Pharma for Anti-Trust Violations in US
Drug major Sun Pharmaceutical Industries on Friday said it is reviewing a complaint filed against it and its subsidiaries by Meijer Inc alleging anti-trust and other violations in connection with Ranbaxy securing market exclusivity for certain products.
-
Lupin Launches Generic Diovan Tablets in US
Lupin Pharmaceuticals Inc, the US-based subsidiary of the company, has launched its Valsartan tablets in strengths of 40 mg, 80 mg, 160 mg and 320 mg in the US market after getting nod from the US Food and Drug Administration (USFDA), Lupin Ltd said in a statement.
-
Drug Pricing Regulator Slaps Rs 300 Crore Penalty on Novartis: Report
Drug major Novartis has been slapped with a Rs 300 crore penalty by the National Pharmaceutical Pricing Authority (NPPA) for overcharging consumers on sale of Voveran, its best-selling painkiller.
-
Novartis reshapes business via deals with GSK and Lilly
The overhaul is part of a major realignment in the global pharmaceuticals industry as it strives to cope with a clampdown in health spending by cash-strapped governments.
-
Big Pharma pushes for US action against India over patent worries: report
Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.
-
Ranbaxy faces more regulatory scrutiny after US ban
Ranbaxy Laboratories Ltd has been hit by more regulatory scrutiny sparked by a US ban on the bulk of its drugs, in a backlash that could bump up compliance costs and erode profitability among some Indian makers of generic drugs.
-
Novartis to cut or transfer up to 4,000 pharma jobs: report
Swiss drugs group Novartis is planning to cut or transfer up to 4,000 jobs, newspaper NZZ am Sonntag reported on Sunday, citing an internal email.
